ReviewPsychopharmacology2012
Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression.
Review in Psychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02070783 (The Effects of ARA290 on the Cognitive and Neural Processing of Emotions in Healthy Volunteers), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of ARA290 on the Cognitive and Neural Processing of Emotions in Healthy Volunteers
Who cites it
34 citing papers in PubMed, 68 citations in OpenAlex.
- Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- Memory in Psychiatric Disorders: A Review.Life (Basel, Switzerland) · 2025Review
- Acute carbamoylated erythropoietin reduces social stress-induced anxiety and depression-related behaviors.Neuropharmacology · 2025Article
- Exploring the diagnostic potential of IL1R1 in depression and its association with lipid metabolism.Frontiers in pharmacology · 2025Article
- Article
- Erythropoietin and Erythropoietin Receptor Levels and Their Diagnostic Values in Drug-naïve Patients with Generalized Anxiety Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Article
- Association of Endogenous Erythropoietin Levels and Iron Status With Cognitive Functioning in the General Population.Frontiers in aging neuroscience · 2022Article
- Lack of association between erythropoietin treatment and risk of depression in patients with end-stage kidney disease on maintenance dialysis: a nationwide database study in Taiwan.Therapeutic advances in chronic disease · 2021Article
- Delaying memory decline: different options and emerging solutions.Translational psychiatry · 2020Review
- Carbamoylated erythropoietin produces antidepressant-like effects in male and female mice.Progress in neuro-psychopharmacology & biological psychiatry · 2020Article
- A Single 60.000 IU Dose of Erythropoietin Does Not Improve Short-Term Aerobic Exercise Performance in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.Frontiers in physiology · 2020Article
- Design and Development of a Behaviorally Active Recombinant Neurotrophic Factor.Drug design, development and therapy · 2020Article
- Neurocognitive Outcome After Treatment With(out) ECMO for Neonatal Critical Respiratory or Cardiac Failure.Frontiers in pediatrics · 2019Review
- Article
- Article
- Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder.Frontiers in psychiatry · 2018Review
- Clinical Characteristics, Life Adversities and Personality Traits in Monozygotic Twins With, at Risk of and Without Affective Disorders.Frontiers in psychiatry · 2018Article
- Affective immunology: where emotions and the immune response converge.Dialogues in clinical neuroscience · 2017Review
- Erythropoietin Pathway: A Potential Target for the Treatment of Depression.International journal of molecular sciences · 2016Review
- Epobis is a Nonerythropoietic and Neuroprotective Agonist of the Erythropoietin Receptor with Anti-Inflammatory and Memory Enhancing Effects.Mediators of inflammation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCurrent pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.
methodsWe systematically reviewed the published findings from animal and human studies exploring the potential of EPO to treat depression-related cognitive dysfunction and depression.
resultsWe identified five animal studies (two in male rats, two in male mice and one in male rats and mice) and seven human proof-of-concept studies (five in healthy volunteers and two in depressed patients) that investigated the above. All of the reviewed animal studies but one and all human studies demonstrated beneficial effects of EPO on hippocampus-dependent memory and antidepressant-like effects. These effects appear to be mediated through direct neurobiological actions of EPO rather than upregulation of red cell mass.
conclusionsThe reviewed studies demonstrate beneficial effects of EPO on hippocampus-dependent memory function and on depression-relevant behavior, thus highlighting EPO as a candidate agent for future management of cognitive dysfunction and mood symptoms in depression. Larger-scale clinical trials of EPO as a treatment for mood and neurocognitive symptoms in patients with mood disorder are therefore warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.